<DOC DOCNO="nw/wsj/14/wsj_1443@1443@wsj@nw@en@on">
<TEXT PARTNO="000">
<COREF ID="16" TYPE="IDENT">Immunex Corp.</COREF> said 0 <COREF ID="16" TYPE="IDENT">its</COREF> scientists isolated <COREF ID="19" TYPE="IDENT">a molecule which *T*-1 may hold potential as a treatment for disruptions of the immune - system , ranging from organ - transplant rejection , to allergies and asthma</COREF> .
<COREF ID="19" TYPE="IDENT">The molecule</COREF> is the mouse version of <COREF ID="20" TYPE="IDENT">a protein called * *PRO*-5 the interleukin - 4 receptor</COREF> .
<COREF ID="21" TYPE="IDENT">IL - 4</COREF> is a hormone which *T*-5 directs the growth and function of white blood cells involved * in the body 's immune response .
<COREF ID="20" TYPE="IDENT">The <COREF ID="21" TYPE="IDENT">IL - 4</COREF> receptor on the surface of such cells</COREF> receives <COREF ID="21" TYPE="IDENT">the hormone 's</COREF> message *PRO* to rally the body 's defense .
But in certain conditions such as autoimmune diseases and allergies and transplant rejection , doctors would like *PRO*-1 to damp the immune response so such cells do n't touch off harmful inflammatory reactions or cell destruction .
A soluble form of <COREF ID="20" TYPE="IDENT">the receptor</COREF> might turn off a specific part of the immune response without general immune suppression , <COREF ID="16" TYPE="IDENT">the company</COREF> said 0 *T*-1 .
<COREF ID="20" TYPE="IDENT">The <COREF ID="21" TYPE="IDENT">IL - 4</COREF> receptor</COREF> is one of <COREF ID="22" TYPE="IDENT">five such receptors 0 *T*-2 to be *-3 developed and tested by <COREF ID="17" TYPE="IDENT"><COREF ID="18" TYPE="APPOS" SUBTYPE="HEAD">Receptech Corp.</COREF> , <COREF ID="18" TYPE="APPOS" SUBTYPE="ATTRIB">a spinoff of <COREF ID="16" TYPE="IDENT">Immunex</COREF></COREF></COREF> , through a proposed $ 30 million *U* initial public offering</COREF> .
<COREF ID="16" TYPE="IDENT">Immunex</COREF> will contract with <COREF ID="17" TYPE="IDENT">the spinoff</COREF> *PRO*-1 to provide the research , development and initial testing of <COREF ID="22" TYPE="IDENT">the new agents</COREF> .
<COREF ID="16" TYPE="IDENT">Immunex</COREF> will have the option *PRO* to buy back <COREF ID="17" TYPE="IDENT">Receptech</COREF> shares after five years .
</TEXT>
</DOC>
